Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors

• DOI: 10.1126/scitranslmed.aaf9418
• Publication Date: 2016-11-17T10:45:23Z
• Authors: Daniel F. Ortiz; Jonathan C. Lansing; Laura Rutitzky; Elma Kurtagic; Thomas Prod’homme; Amit Choudhury; Nathaniel Washburn; Naveen Bhatnagar; Christopher Beneduce; Kimberly Holte; Robert Prenovitz; Matthew Child; Jason Killough; Steven Tyler; Julia Brown; Stephanie Nguyen; Inessa Schwab; Maurice Hains; Robin Meccariello; Lynn Markowitz; Jing Wang; Radouane Zouaoui; Allison Simpson; Birgit Schultes; Ishan Capila; Leona Ling; Falk Nimmerjahn; Anthony M. Manning; Carlos J. Bosques
• Keywords: Valency; Immune complex; Immune receptor; Antigen-Antibody Complex

An engineered trivalent Fc drug candidate is a potent inhibitor of FcγR-driven immune cell activation and autoimmune diseases in animal models.